The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a second research grant of $2.5 million to Selonterra to advance the California-based company’s preclinical development of new therapeutic compounds targeting the genetic causes of Parkinson’s disease. Selonterra specifically will be testing whether compounds that…

The number of active Parkinson’s disease clinical trials has remained relatively stable since 2019, but many investigational therapies — especially disease-modifying treatments intended to slow or stop disease progression — are failing to move forward from Phase 2 to Phase 3 trials, according to a report. A wide…

Note: This story was updated March 27, 2024, to correct that the Michael J. Fox Foundation is not funding the LEARNS study. Merck, known as MSD outside the U.S. and Canada, has joined the observational LEARNS study to investigate the potential of digital biomarkers to evaluate and predict disease…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded an $873,000 grant to Vesper Bio to advance the preclinical development of small-molecule therapies aiming to increase progranulin levels in people with Parkinson’s disease. Low levels of progranulin, a protein critical for immune activity and…

Led by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), an international group of patients, researchers, and industry leaders has proposed a framework for defining and staging Parkinson’s disease based on its underlying biology rather than by hallmark disease symptoms. Called the neuronal alpha-synuclein disease integrated…

To better care for the growing number of people with Parkinson’s disease and their families, the Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program. The two-year fellowship supports medical centers in training a new generation of…

Two small molecules in the pipeline of Lucy Therapeutics helped nerve cells (neurons) keep their mitochondria healthier and reduced the levels of  alpha-synuclein, a protein that builds as toxic clumps in the brain of people with Parkinson’s disease. These molecules, called LucyTx-1209 and LucyTx-1212, also were seen…

A dozen runners who live with Parkinson’s disease (PD) hope to heighten awareness of the neurodegenerative disorder and raise funds for research by taking on one of the nation’s most demanding relay road races — the Blue Ridge Relay — on Sept. 9-10. The 12 runners, who’ve dubbed themselves…

Koneksa has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to investigate the potential of digital biomarkers to evaluate and predict disease progression in people with Parkinson’s disease. Digital biomarkers have the potential to aid in diagnosing Parkinson’s and allowing patients…

The healthcare technology company Koneksa and Northwestern University plan to begin recruiting patients in the third quarter of this year for a study aimed at measuring the severity of vocal abnormalities that can occur in Parkinson’s disease. The clinical trial, which is expected to be completed in 2024, will…